Drugs / hOKT3γ1 (Ala-Ala)
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00285194 | Apr 2000 → Jan 2004 | hypoglycemia, type 1 diabetes mellitus | University of Minnesota | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | hOKT3γ1 (Ala-Ala) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00285194 ↗ |
| Known as | hOKT3gamma1 (Ala-Ala) | “Induction immunosuppression, which began 2 days pretransplant, included the Fc receptor nonbinding humanized anti-CD3 monoclonal antibody hOKT3gamma1 (Ala-Ala) and sirolimus.” PMID 14961992 ↗ Mar 2004 |
| Modality | Monoclonal antibody | “the FcR-nonbinding anti-CD3 monoclonal antibody hOKT3γ1 (Ala-Ala)” NCT00285194 ↗ |